表紙
市場調査レポート

バイオシミラーの世界市場 - 2016〜2020年

Global Biosimilars Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 232659
出版日 ページ情報 英文 152 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
バイオシミラーの世界市場 - 2016〜2020年 Global Biosimilars Market 2016-2020
出版日: 2016年08月01日 ページ情報: 英文 152 Pages
概要

バイオシミラーは、特許期間が満了したオリジナルのバイオ医薬品の後続品で、オリジナル品と同じMOA (作用機序) により、同じ対象疾患に対する治療を目的としています。バイオシミラーはオリジナル品と多くの共通点を持ちますが、完全な同一品という訳ではありません。バイオシミラーの世界市場は2016年から2020年までの期間において55.52%ものCAGR (年平均成長率) にて成長が続くと予測されます。

当レポートでは、バイオシミラーの世界市場を取り上げ、市場成長促進要因や市場が抱える課題、市場動向、また市場競争状況に関する詳細な調査を通じて、市場の現状分析ならびに2016年から2020年までの将来予測を行っています。

第1章 エグゼクティブ・サマリー

第2章 当レポートのカバー範囲

  • 市場概要
  • 主要ベンダー製品
  • 前提条件

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 序論

  • 市場に関する重要事項
  • バイオシミラー:概要
  • バイオシミラーと低分子ジェネリック医薬品の比較分析
  • バイオシミラーの市場機会
  • 新規参入企業にとっての課題
  • バイオベター

第5章 研究開発パイプライン上の各種医薬品

第6章 市場概況

  • 市場概要
  • ファイブフォース分析

第7章 バイオシミラーの世界市場 - 適応症別市場分類

  • 血液疾患用バイオシミラーの世界市場
  • 市場概要
  • ガン治療用バイオシミラーの世界市場
  • 慢性疾患および自己免疫疾患用バイオシミラーの世界市場
  • 成長ホルモン欠乏症用バイオシミラーの世界市場
  • 感染症用バイオシミラーの世界市場
  • その他

第8章 バイオシミラーの世界市場 - エンドユーザー別市場分類

  • 病院
  • 薬局・薬店

第9章 バイオシミラーの世界市場 - 地域別市場分類

  • 地域別に見たバイオシミラーの世界市場 - 2015〜2020年
  • 欧州・中東・アフリカ地域のバイオシミラー市場
  • アジア太平洋地域のバイオシミラー市場
  • 南北アメリカ地域のバイオシミラー市場

第10章 バイオシミラーの世界市場 - 成長促進要因

  • 特許期間が満了した医薬品数の増加
  • 費用効果が高い治療の必要性
  • バイオシミラーに対する保険払い戻しの利点
  • 有利な政府規制
  • 将来性の高い研究開発パイプライン段階の医薬品

第11章 市場成長促進要因がもたらす影響

第12章 バイオシミラーの世界市場 - 課題

  • バイオシミラーの処方に対して医師が持つ抵抗感
  • 製造上の数多くの複雑性
  • 効かない医薬品を作ってしまうことに関するリスク
  • バイオシミラーの入手性の悪さ
  • 臨床試験を行うに当たっての被験患者募集の難しさ

第13章 市場成長促進要因と市場の課題とがもたらす影響

第14章 バイオシミラーの世界市場 - 動向

  • バイオシミラーの台頭
  • バイオシミラー製造のアウトソーシング
  • 研究開発に多くの投資を行う必要性
  • 新興諸国市場における高成長
  • 戦略的企業提携件数の増加

第15章 ベンダー情勢

  • 市場競争シナリオ
  • Sandoz
  • Hospira
  • Teva Pharmaceuticals
  • STADA
  • Biocon
  • Celltrion
  • Dr. Reddy's
  • その他の有力ベンダー

第16章 付録

第17章 Technavioについて

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR10077

About Biosimilars

Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator's product. They have many similarities, but are not identical to, the reference biopharmaceutical product.

Technavio's analysts forecast the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global biosimilars market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products such as somatropin, erythropoietin, colony-stimulating factors (CSF), interferons, interleukins, insulin and insulin analogs, follicle stimulating hormones (FSH), monoclonal antibodies (mAbs), and low molecular weight heparins (LMWH).

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Hospira
  • Sandoz
  • STADA
  • Teva Pharmaceuticals

Other Prominent Vendors

  • 3SBio
  • Accord Healthcare
  • AET Biotech
  • Allergan
  • Alvartis Pharma
  • Amega Biotech
  • Amgen
  • Apotex
  • Aspen
  • AstraZeneca
  • Aurobindo Pharma
  • Baxter
  • Bharat Serums
  • Bio Sidus
  • Biogen
  • Bionovis
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Boston Oncology
  • Cipla
  • Coherus Biosciences
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • Gedeon Richter
  • GeneScience Pharmaceuticals
  • GSK
  • Hetero Drugs
  • iBio
  • Intas Pharmaceuticals
  • JCR Pharmaceuticals
  • LG Lifesciences
  • Lonza
  • Merck
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Novartis
  • Pfenex
  • Pfizer
  • Ranbaxy Laboratories
  • Roche Holding
  • Samsung Biologics
  • Sanofi
  • Synthon
  • Wockhardt
  • Zydus Cadila Healthcare

Market driver

  • Rise in number of patent expiries
  • For a full, detailed list, view our report

Market challenge

  • Physicians reluctance to prescribe biosimilars
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Biosimilars: Overview
  • Comparative analysis of biosimilars and generic small molecules
  • Biosimilars market opportunities
  • Challenges for new entrants
  • Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape

  • Market overview
  • Five forces analysis

PART 07: Market segmentation by application

  • Global blood disorders biosimilars market
  • Market overview
  • Global oncology biosimilars market
  • Global chronic and autoimmune diseases biosimilars market
  • Global growth hormone deficiency biosimilars market
  • Global infectious diseases biosimilars market
  • Others

PART 08: Market segmentation by end-user

  • Hospitals
  • Retail pharmacies

PART 09: Geographical segmentation

  • Global biosimilars market by geographical segmentation 2015-2020
  • Biosimilars market in EMEA
  • Biosimilars market in APAC
  • Biosimilars market in Americas

PART 10: Market drivers

  • Rise in number of patent expiries
  • Need for cost-effective treatment
  • Reimbursement benefits for biosimilars
  • Favorable government regulations
  • Promising pipeline

PART 11: Impact of drivers

PART 12: Market challenges

  • Physicians reluctance to prescribe biosimilars
  • Multiple manufacturing complexities
  • Risks related to drug failure
  • Limited availability of biosimilar products
  • Difficulties in patient recruitment for conducting clinical trials

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Emergence of biosimilars
  • Outsourcing of biosimilar manufacturing activities
  • Need for high investment in R&D
  • High growth in the emerging markets
  • Rising number of strategic collaborations

PART 15: Vendor landscape

  • Competitive scenario
  • Sandoz
  • Hospira
  • Teva Pharmaceuticals
  • STADA
  • Biocon
  • Celltrion
  • Dr. Reddy's
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global biosimilar market snapshot
  • Exhibit 03: Key buying criteria for biosimilars 2015
  • Exhibit 04: Major timelines in global biosimilars market 2014-2020
  • Exhibit 05: Impact of key customer segments on market 2015
  • Exhibit 06: Definition of biosimilars in different regions
  • Exhibit 07: Comparison between biosimilars and generic small molecules
  • Exhibit 08: Factors affecting biologics and biosimilars market
  • Exhibit 09: Impact of biosimilars cost savings on various sectors
  • Exhibit 10: Factors affecting success of biosimilars
  • Exhibit 11: Biosimilars industry: Point-of-view
  • Exhibit 12: Factors influencing uptake of biosimilars
  • Exhibit 13: Global biosimilars market: Strategic factors for new market entrants
  • Exhibit 14: Challenges for new entrants
  • Exhibit 15: Bio-betters and its impact on market
  • Exhibit 16: Global biosimilars market: Pipeline snapshot 2015
  • Exhibit 17: Pipeline portfolio: Global biosimilars market 2015
  • Exhibit 18: Number of approved biosimilars in regulated and semi-regulated markets
  • Exhibit 19: Patent expirations of major biologics from 2000-2030
  • Exhibit 20: Global biosimilars market snapshot: Developed and emerging markets 2015
  • Exhibit 21: Patient assistance programs by vendors
  • Exhibit 22: Global biosimilars market 2015-2020 ($ billions)
  • Exhibit 23: Global spending for biosimilars 2015-2020 ($ billions)
  • Exhibit 24: Global biosimilars market: Key metrics analysis snapshot
  • Exhibit 25: Current and future trends in global biosimilars market
  • Exhibit 26: Impact of drivers and challenges on global biosimilars market
  • Exhibit 27: Five forces analysis
  • Exhibit 28: Global biosimilars market: Segmentation by application (2015-2020)
  • Exhibit 29: Applications of biosimilars and its impact on growth of market
  • Exhibit 30: Global biosimilars market: Segmentation by application 2015
  • Exhibit 31: Global biosimilars market segmentation: Growth cycle analysis
  • Exhibit 32: Global blood disorders market biosimilar 2015-2020 ($ billions)
  • Exhibit 33: Opportunity analysis of global blood disorders biosimilar market by type of application
  • Exhibit 34: Global oncology biosimilar market 2015-2020 ($ billions)
  • Exhibit 35: Opportunity analysis of global oncology biosimilar market by type of application
  • Exhibit 36: Population aged 60 years and over (millions)
  • Exhibit 37: Global chronic and autoimmune diseases biosimilars market 2015-2020 ($ millions)
  • Exhibit 38: Opportunity analysis of chronic and autoimmune diseases biosimilars market by application
  • Exhibit 39: Global growth hormone deficiency biosimilars market 2015-2020 ($ millions)
  • Exhibit 40: Opportunity analysis of global growth hormone deficiency biosimilars market
  • Exhibit 41: Global infectious diseases biosimilars market 2015-2020 ($ millions)
  • Exhibit 42: Opportunity analysis of infectious diseases biosimilars market by application
  • Exhibit 43: Global biosimilars market segmentation by application 2015
  • Exhibit 44: Biosimilars market segmentation by end-user 2015
  • Exhibit 45: Global biosimilars market: Geography outlook (2015-2020)
  • Exhibit 46: Global biosimilars market: Geography outlook 2015
  • Exhibit 47: Revenue/growth outlook in different countries/regions 2015
  • Exhibit 48: Biosimilar market landscape: Country analysis
  • Exhibit 49: Market penetration of originators and biosimilars in different regions
  • Exhibit 50: Biosimilars market in EMEA 2015-2020 ($ billions)
  • Exhibit 51: Biosimilars market in EMEA by region 2015
  • Exhibit 52: Guidelines for biosimilars in EU
  • Exhibit 53: Timeline of biosimilars in Europe
  • Exhibit 54: Geographical segmentation in Europe 2015
  • Exhibit 55: Patent expirations of major biologics in Europe
  • Exhibit 56: Key leading countries in EMEA 2015
  • Exhibit 57: Biosimilars market in Europe 2015-2020 ($ billions)
  • Exhibit 58: Europe biosimilars market: Opportunity analysis
  • Exhibit 59: Approved marketed products in Europe
  • Exhibit 60: Key stake holders in EU biosimilars market
  • Exhibit 61: PEST analysis: Biosimilars market in Europe 2015
  • Exhibit 62: Biosimilars market in Germany 2015-2020 ($ millions)
  • Exhibit 63: Biosimilars market in UK 2015-2020 ($ millions)
  • Exhibit 64: Biosimilars market in France 2015-2020 ($ millions)
  • Exhibit 65: Biosimilars market in Italy 2015-2020 ($ millions)
  • Exhibit 66: Biosimilars market in Spain 2015-2020 ($ millions)
  • Exhibit 67: Biosimilars market in APAC 2015-2020 ($ billions)
  • Exhibit 68: Biosimilars market in APAC by country 2015
  • Exhibit 69: Key leading countries in APAC 2015
  • Exhibit 70: Biosimilars market in China 2015-2020 ($ millions)
  • Exhibit 71: China biosimilars market: Opportunity analysis
  • Exhibit 72: PEST analysis: Biosimilars market in China
  • Exhibit 73: Timeline for development of biosimilars in India
  • Exhibit 74: Challenges and strategies in developing biosimilars in India
  • Exhibit 75: Biosimilars market in India 2015-2020 ($ millions)
  • Exhibit 76: India biosimilars market: Opportunity analysis
  • Exhibit 77: Approved biosimilars in India
  • Exhibit 78: PEST analysis: Biosimilars market in India 2015
  • Exhibit 79: Review process for biosimilars in Japan
  • Exhibit 80: Biosimilars approved by PMDA in Japan
  • Exhibit 81: Biosimilars market in Japan 2015-2020 ($ millions)
  • Exhibit 82: Biosimilars market in Japan: Opportunity analysis
  • Exhibit 83: PEST analysis: Biosimilars market in Japan 2015
  • Exhibit 84: Biosimilars market in Americas 2015-2020 ($ billions)
  • Exhibit 85: Approvals of biologicals versus biosimilars via public health service act (PHSA)
  • Exhibit 86: Timeline of biosimilar regulations in US
  • Exhibit 87: Approval process for biosimilars in US
  • Exhibit 88: Benefits of biosimilars to US healthcare system
  • Exhibit 89: Patent expirations of major biologics in US
  • Exhibit 90: Biosimilars market in US 2015-2020 ($ million)
  • Exhibit 91: Biosimilars market in US: Opportunity analysis
  • Exhibit 92: Role of stakeholders in creating awareness in US
  • Exhibit 93: PEST analysis: Biosimilars market in US 2015
  • Exhibit 94: Global biosimilars market: Key leading countries (2015)8
  • Exhibit 95: Patent analysis of biologicals in US
  • Exhibit 96: Patent analysis of biologicals in Europe
  • Exhibit 97: Impact of drivers
  • Exhibit 98: Key reasons as to why physicians are reluctant to prescribe biosimilar6
  • Exhibit 99: Impact of drivers and challenges
  • Exhibit 100: Global biosimilars market: Impact assessment of key trends
  • Exhibit 101: Competitive assessment of vendors
  • Exhibit 102: Key vendors: Geographical presence 2015
  • Exhibit 103: Mergers, acquisitions and partnership assessment of major vendors in global biosimilars market
  • Exhibit 104: Sandoz: YoY revenue and growth rate of biosimilars 2014-2015 ($ millions)
  • Exhibit 105: Sandoz: Metrics analysis
  • Exhibit 106: Hospira: Metrics analysis4
  • Exhibit 107: Teva Pharmaceuticals: Metrics analysis6
  • Exhibit 108: STADA: Metrics analysis
  • Exhibit 109: Biocon: Metrics analysis
  • Exhibit 110: Celltrion: Metrics analysis
  • Exhibit 111: Dr. Reddy's: Metrics analysis
Back to Top